The Food and Drug Administration (FDA) issued a warning on October 13, 2010, for patients being treated for osteoporosis with drugs containing bisphosphonates that they are at higher risk or developing femoral (thigh bone) fractures. The warning comes because the rare type of fractures, subtrochanteric femur fractures, that have been reported are mostly in patients that have been treated with bisphonphonates for osteoporosis.
The FDA is unsure as to what the optimal duration for bisphosphonates treatment is–however, the unusal fractures are occuring in patients who have been prescribed the drug for a period exceding five years.
For more information, please visit the Food and Drug Administration’s website.
If you or someone you know has suffered a fracture as a result bisphosphonates treatments, please contact Sheller, P.C. at 1-800-883-2299.